Merck Opens €59 Million CDMO Facility to Address Demand for Critical Cancer Therapies

Expansion doubles production of the most highly potent active pharmaceutical ingredients (HPAPIs)

27-Jun-2022 - USA

Merck announced that its Life Science business sector has doubled its high-potent active pharmaceutical ingredients (HPAPI) production capacity with the expansion of its facility in Verona, near Madison, Wisconsin, USA. This new €59 million, 70,000 square foot facility, officially opened, brings 50 new jobs to the area. 

Merck KGaA

“There is an increasing demand for HPAPIs due to their effectiveness against cancer at lower doses and the trend towards more targeted therapeutics. Lower-doses of these therapies reduce the negative side effects for patients who are taking on this critical fight,” said Dirk Lange, head of Life Science Services, Life Science, at Merck. “Increasing capacity at our state-of-the-art CDMO facility in Verona, Wisconsin will allow us to meet the need for these key cancer treatment components.”

HPAPIs are a critical element of targeted therapies due to their extremely effective cell-killing abilities at low doses, resulting in reduced side effects for patients. They are used in novel cancer therapies, including antibody drug conjugates (ADCs), which are changing the landscape of cancer treatments.

Other news from the department manufacturing

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

Last viewed contents

New approach to the sensible utilisation of carbon dioxide from car exhaust gases - "A method has been discovered that uses impure CO2 streams and enables a breakthrough in the synthesis of valuable chemicals and pharmaceuticals"

New approach to the sensible utilisation of carbon dioxide from car exhaust gases - "A method has been discovered that uses impure CO2 streams and enables a breakthrough in the synthesis of valuable chemicals and pharmaceuticals"

Acambis completes enrollment of Phase 3 JE vaccine trials ahead of schedule

Merck Discontinues Development of SARS-CoV-2/COVID-19 Vaccine Candidates - Company continues Development of Two Investigational Therapeutic Candidates

Merck Discontinues Development of SARS-CoV-2/COVID-19 Vaccine Candidates - Company continues Development of Two Investigational Therapeutic Candidates

American Peptide Company Announces Expansion of Its GMP Manufacturing Facility - Company expands capacity to accommodate large scale peptide production for growing customer base

New biotech company Confo Therapeutics launched by VIB and Vrije Universiteit Brussel - Capricorn Venture Partners leads 1st financing round of € 3 million

Merck Appoints Richard R. DeLuca Jr. as President, Merck Animal Health - Former Becton Dickinson and Wyeth Executive Joins Merck

Movetis starts phase III clinical trial with prucalopride in male patients with chronic constipation

Voyager Therapeutics & Genzyme collaborate to develop and commercialize novel AAV gene therapies for patients with CNS Disorders

Aseptika Granted United States Patent for Biomarkers for Respiratory Infection Onset

Vertex Pharmaceuticals: Start of Phase II Clinical Development for Investigational Oral Hepatitis C Virus Protease Inhibitor

Eurofins expands its footprint in Asia with the acquisition of Lab Frontier in South Korea